Cypress Bioscience, Inc. (NASDAQ:CYPB) today confirmed that it received a revised offer from Ramius LLC to acquire all of the outstanding common shares of Cypress common stock for $5.50 per share in cash that it does not already own.
Cypress’ Board of Directors, with the assistance of its financial advisors, has been actively engaged in evaluating a broad range of strategic alternatives. Cypress’ Board will carefully evaluate the revised Ramius offer as part of its ongoing evaluation.
Jefferies & Company, Inc. and Perella Weinberg Partners are serving as financial advisors to Cypress and Cooley LLP, Sullivan & Cromwell LLP and Potter Anderson & Corroon LLP are serving as its legal advisors.
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services in the United States. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company also provides personalized medicine services, including Avise MCV, a test that aids in the diagnosis and prognosis of rheumatoid arthritis; and Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate. Cypress Bioscience, Inc. has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; and a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran. The company was founded in 1981 and is based in San Diego, California.
To learn more about CYPB visit: http://www.cypressbio.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.